The submission, which the company previously has announced its’ intention to submit, seeks to expand the therapeutic indication of Pepaxti (melflufen) to include adult patients with multiple myeloma who have received at least two prior lines of therapies (3rd line+), and whose disease is refractory to lenalidomide and the last line of therapy. Currently, Pepaxti is indicated for adult patients who have received at least three prior lines of therapies and are triple-class refractory (4th line+).

The potential approval for this broader indication would address an important medical need and strengthen the position of Pepaxti in the treatment landscape for relapsed, refractory multiple myeloma (RRMM). An approved application would significantly expand the potential addressable market for Pepaxti, doubling the current addressable patient population in Europe. In addition, third-line patients are estimated to undergo, on average, double the number of treatment cycles compared to the current label, potentially driving a powerful clinical and commercial multiplier effect.

Based on standard regulatory procedures and the successful validation of the file, Oncopeptides expects to receive a CHMP (Committee for Medicinal Products for Human Use) opinion between September and November 2026. Following a positive CHMP opinion, a final European Commission (EC) decision is anticipated within 30 to 60 days.

The company's previously communicated European market potential of SEK 1.5 billion reflects only the current fourth-line indication and does not include the substantial added commercial potential that a third-line approval would unlock.

For more information, including questions and answers for investors, please visit www.oncopeptides.com